In our study, the distribution of SCLC based on the presence of ASCL1 and NEUROD1 was as follows: (1) ASCL1‐only 48.27%, (2) NEUROD1‐only 13.79%; (3) ASCL1/NEUROD1 double‐positive 20.69%; and (4) ASCL1/NEUROD1 double‐negative 17.24% (Figure 1D). This evidence concerns the gene NEUROD1 and small cell lung carcinoma.